Jakub Karol Tambor

Mr. Jakub Karol Tambor

Medical University of Lodz, Łódź, Łódzkie, Poland
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PSPaulina Sokołowska
Paulina Sokołowska
AWAnna Wiktorowska-Owczarek
Anna Wiktorowska-Owczarek
JTJakub Karol Tambor
Jakub Karol Tambor
SGSebastian Gawlak-Socka
Sebastian Gawlak-Socka
EKEdward Kowalczyk
Edward Kowalczyk
Marta Jóźwiak-BębenistaMarta Jóźwiak-Bębenista
Marta Jóźwiak-Bębenista
Endoplasmic reticulum (ER) stress is a significant player in the pathophysiology of various neurodegenerative and neuropsychiatric disorders. Despite the established link between ER stress and inflammatory pathways, there remains a need for deeper exploration of the specific cellular mechanisms underlying ER stress-mediated neuroinflammation. This study aimed to investigate how the severity of ER stress (triggered by different concentrations of tunicamycin) can impact the release of proinflammatory cytokines IL-6 and IL-8 from astrocytes and microglia, comparing the effects with those induced by well-known immunostimulants—tumor necrosis factor alpha (TNF-α) or lipopolysaccharide (LPS). Mild ER stress has a distinct effect on the cytokine release compared to more intense stress levels, i.e., diminished IL-6 production was accompanied by an increase in IL-8 level, which was significantly more pronounced in astrocytes than in microglia. On the contrary, prolonged or more severe ER stress induced inflammation in glial cells, leading to a time- and concentration-dependent buildup of proinflammatory IL-6, but unlike inflammatory agents, an ER stress inducer diminished IL-8 secretions by glial cells. The differences could hold importance in identifying ER stress markers as potential drug targets for the treatment of neurodegenerative diseases or mood disorders, yet this requires confirmation in more complex animal studies.

26 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
PSPaulina Sokołowska
Paulina Sokołowska
AWAnna Wiktorowska-Owczarek
Anna Wiktorowska-Owczarek
JTJakub Karol Tambor
Jakub Karol Tambor
SGSebastian Gawlak-Socka
Sebastian Gawlak-Socka
EKEdward Kowalczyk
Edward Kowalczyk
Marta Jóźwiak-BębenistaMarta Jóźwiak-Bębenista
Marta Jóźwiak-Bębenista
Background: Endoplasmic reticulum (ER) stress is a significant player in the pathophysiology of various neurodegenerative and neuropsychiatric disorders. Despite the established link between ER stress and inflammatory pathways, there remains a need for deeper exploration of the specific cellular mechanisms underlying ER stress-mediated neuroinflammation. Methods: This study aimed to investigate how severity of ER stress can impact the release of proinflammatory cyto-kines IL-6 and IL-8 from astrocytes and microglia, comparing the effects with those induced by well-known immunostimulants - tumor necrosis factor alpha (TNF-α) or lipopolysaccharide (LPS). Results: Mild ER stress has a distinct effect on the cytokine release compared to more intense stress levels, i.e. diminished IL-6 production was accompanied by an increase in IL-8 level, which was significantly more pronounced in astrocytes than in microglia. On the contrary, prolonged or more severe ER stress induced inflammation in glial cells, leading to a time- and concentration-dependent buildup of pro-inflammatory IL-6 but unlike inflammatory agents, ER stress inducer diminished IL-8 secretions by glial cells. Conclusion: The differences could hold importance in identifying ER stress markers as potential drug targets for treatment of neurodegenerative diseases or mood disorders, yet it requires confirmation in more complex animal studies.

27 February 2023 in Medical Science Pulse
Verified
Journal Article
Closed access
MKMarta Kozłowska
Marta Kozłowska
SKSzymon Kotarba
Szymon Kotarba
JTJakub Karol Tambor
Jakub Karol Tambor
MWMateusz Winiarski
Mateusz Winiarski
HMHanna Moczulska
Hanna Moczulska
MBMaciej Borowiec
Maciej Borowiec
Background: Parkinsons disease (PD) is a neurodegenerative disease in which dopaminergic neurons are damaged, and Lewy bodies accumulate in the brain, leading to both motor and non-motor symptoms. Currently, no treatment is available to slow down or reverse disease progression. The need to find new solutions has prompted research interest in gene therapy. Aim of the study: The purpose of this review is to analyze a selection of completed clinical trials on gene therapy in PD and their possible implementation in treatment. Material and Methods: Clinical trials were selected from the ClinicalTrials.gov database using the following search criteria: Parkinsons disease, gene therapy, and completed status. Trials that were ongoing, terminated, preclinical, or with different research subjects were excluded. PubMed and Google Scholar databases were also searched for neuropathology, symptoms, and treatment recommendations for PD. The results of reviewed clinical trials have been checked in terms of the efficacy and safety of the investigated therapies in the treatment of PD. Results: We analyzed 7 completed clinical trials, namely VY-AADC01 (NCT01973543), AAV-GAD (NCT00195143), ProSavin (NCT00627588), AAV2-GDNF (NCT01621581), CERE-120 (NCT00252850), VY-AADC01 (NCT03065192), and CERE-120 (NCT00985517) with a total of 152 patients. Five of the studies had published results and four of these five had satisfactory results. VY-AADC01, AAV-GAD, and CERE-120 were found to be safe and potentially effective in the treatment of PD, while ProSavin demonstrated insufficient effectiveness. Conclusions: There is limited available data regarding completed clinical trials for PD gene therapy, with a small number of patients, making it difficult to give a final statement on the possibility of using gene therapy to treat PD. However, the clinical trials reviewed herein show promising results with the potential to revolutionize the treatment of PD.